Payment overview · 2025
General Payments
$1,641.46
72 reported records · 23 companies
Healthcare provider profile · identity verified
Steven Patrickl Unkel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FARMERVILLE, LA · NPI 1770544124
Verified facts
What the public records show
CMS Open Payments records show Steven Patrickl Unkel, M.D. received $1,641.46 in general payments during 2025 across 72 reported records.
Vanda Pharmaceuticals Inc. accounted for 13.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Nuedexta, Ozempic, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 365 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 365 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $225.77 | 13.8% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $207.67 | 12.7% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $201.96 | 12.3% | 8 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $197.08 | 12.0% | 9 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $190.71 | 11.6% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $144.08 | 8.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $57.87 | 3.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 2.7% | 1 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $44.12 | 2.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.44 | 2.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.36 | 2.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.83 | 2.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.91 | 2.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.53 | 1.4% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.30 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.78 | 1.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.49 | 1.2% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.67 | 1.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.48 | 1.1% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.97 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.29 | 1.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $15.29 | 0.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.86 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,596.46 | 71 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $225.77 | 6 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $197.08 | 9 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $190.71 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $183.89 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $144.08 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $130.16 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $89.20 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $74.36 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $71.13 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $66.62 | 5 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $63.09 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $57.87 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $57.87 | 3 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $44.12 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.36 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $34.83 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $34.25 | 2 | 2025 |
Source payment records
|
|||||
| NUEDEXTA Normalized: nuedexta |
Drug | Otsuka America Pharmaceutical, Inc. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $3.15 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $3.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 79 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 365 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 102 | exact normalized | Medicare Part D |
| NUEDEXTA nuedexta |
2025 | Nuedexta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
102 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
365 | 68 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
233 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
365 | 68 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
202 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
92 | 18 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1049 | 190 |
| Amlodipine Besylate | Amlodipine Besylate | 1012 | 195 |
| Potassium Chloride | Potassium Chloride | 729 | 138 |
| Gabapentin | Gabapentin | 710 | 123 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 678 | 101 |
| Furosemide | Furosemide | 590 | 114 |
| Lisinopril | Lisinopril | 561 | 107 |
| Indapamide | Indapamide | 551 | 97 |
| Omeprazole | Omeprazole | 536 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 479 | 77 |
| Carvedilol | Carvedilol | 471 | 79 |
| Pioglitazone Hcl | Pioglitazone Hcl | 429 | 91 |
| Jardiance | Empagliflozin | 365 | 68 |
| Spironolactone | Spironolactone | 353 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 351 | 63 |
| Celecoxib | Celecoxib | 350 | 74 |
| Tramadol Hcl | Tramadol Hcl | 350 | 70 |
| Zolpidem Tartrate | Zolpidem Tartrate | 349 | 49 |
| Quetiapine Fumarate | Quetiapine Fumarate | 335 | 53 |
| Metformin Hcl | Metformin Hcl | 309 | 69 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 304 | 43 |
| Doxepin Hcl | Doxepin Hcl | 298 | 60 |
| Trazodone Hcl | Trazodone Hcl | 285 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 279 | 51 |
| Losartan Potassium | Losartan Potassium | 263 | 51 |
| Perindopril Erbumine | Perindopril Erbumine | 253 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 253 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 252 | 47 |
| Allopurinol | Allopurinol | 245 | 42 |
| Sertraline Hcl | Sertraline Hcl | 242 | 47 |
| Eliquis | Apixaban | 233 | 35 |
| Mirtazapine | Mirtazapine | 231 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 204 | 40 |
| Mounjaro | Tirzepatide | 202 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 195 | 44 |
| Meloxicam | Meloxicam | 195 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 184 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 175 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 29 |
| Azelastine Hcl | Azelastine Hcl | 168 | 52 |
| Methylprednisolone | Methylprednisolone | 158 | 116 |
| Minoxidil | Minoxidil | 158 | 31 |
| Pregabalin | Pregabalin | 153 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 151 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 150 | 29 |
| Warfarin Sodium | Warfarin Sodium | 150 | 14 |
| Donepezil Hcl | Donepezil Hcl | 148 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 145 | 21 |
| Atenolol | Atenolol | 132 | 22 |
| Aripiprazole | Aripiprazole | 126 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 125 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 124 | 49 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 121 | 28 |
| Simvastatin | Simvastatin | 121 | 24 |
| Famotidine | Famotidine | 118 | 26 |
| Topiramate | Topiramate | 114 | 27 |
| Estradiol | Estradiol | 113 | 29 |
| Clonazepam | Clonazepam | 108 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 103 | 22 |
| Linzess | Linaclotide | 102 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 100 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 97 | 18 |
| Entresto | Sacubitril/Valsartan | 96 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 93 | 27 |
| Candesartan Cilexetil | Candesartan Cilexetil | 92 | 14 |
| Ranolazine Er | Ranolazine | 92 | 22 |
| Trulicity | Dulaglutide | 92 | 18 |
| Meclizine Hcl | Meclizine Hcl | 90 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 89 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 16 |
| Clonidine Hcl | Clonidine Hcl | 87 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 87 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 15 |
| Olanzapine | Olanzapine | 86 | 13 |
| Promethazine Hcl | Promethazine Hcl | 86 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 83 | 32 |
| Gemfibrozil | Gemfibrozil | 83 | 18 |
| Ibuprofen | Ibuprofen | 83 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 83 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 81 | 19 |
| Farxiga | Dapagliflozin Propanediol | 79 | 15 |
| Levetiracetam | Levetiracetam | 79 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 73 | 59 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 72 | suppressed |
| Finasteride | Finasteride | 71 | 17 |
| Ketoconazole | Ketoconazole | 71 | 25 |
| Lamotrigine | Lamotrigine | 71 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 70 | 11 |
| Buspirone Hcl | Buspirone Hcl | 69 | suppressed |
| Ozempic | Semaglutide | 67 | 18 |
| Memantine Hcl | Memantine Hcl | 64 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 64 | 19 |
| Alprazolam | Alprazolam | 63 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 61 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 61 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 61 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 60 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 11 |
| Nifedipine Er | Nifedipine | 56 | 11 |
| Lorazepam | Lorazepam | 55 | suppressed |
| Nitroglycerin | Nitroglycerin | 55 | 14 |
| Montelukast Sodium | Montelukast Sodium | 54 | 11 |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 52 | 11 |
| Rexulti | Brexpiprazole | 51 | suppressed |
| Amoxicillin | Amoxicillin | 49 | 38 |
| Modafinil | Modafinil | 49 | suppressed |
| Metolazone | Metolazone | 48 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 41 |
| Fluconazole | Fluconazole | 46 | 31 |
| Digoxin | Digoxin | 43 | suppressed |
| Ramipril | Ramipril | 43 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Colchicine | Colchicine | 40 | 15 |
| Naproxen | Naproxen | 40 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | 11 |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Bumetanide | Bumetanide | 38 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 12 |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Prednisone | Prednisone | 36 | 16 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | 12 |
| Trandolapril | Trandolapril | 33 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 32 | suppressed |
| Mupirocin | Mupirocin | 32 | 17 |
| Nystatin | Nystatin | 32 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 30 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 30 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 27 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 23 | 19 |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Vraylar | Cariprazine Hcl | 23 | suppressed |
| Xifaxan | Rifaximin | 23 | suppressed |
| Clonidine | Clonidine | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 22 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Kerendia | Finerenone | 18 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 17 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Progesterone | Progesterone, Micronized | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 14 |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Volnea | Desog-E.Estradiol/E.Estradiol | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Exelon | Rivastigmine | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,641.46 · 72 records | Vanda Pharmaceuticals Inc. | AIRSUPRA, ARISTADA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, COBENFY, CREON, Cologuard Collection Kit, FANAPT, FARXIGA, GVOKE HYPOPEN, INGREZZA, JARDIANCE, LINZESS, LYBALVI, Motpoly XR, NUEDEXTA, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, Tymlos, UBRELVY, VRAYLAR, WAKIX, Wegovy, ZERBAXA, Zunveyl | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error